COMBINE
2006
Combined Pharmacotherapies and Behavioural Interventions
In 1,383 adults with alcohol dependence, medical management plus naltrexone or combined behavioural intervention reduced heavy-drinking days relative to placebo or acamprosate, with no additive effect.
Result
Primary endpoint: Percent days abstinent and time to heavy-drinking relapse
Naltrexone (HR 0.72) and CBI each effective with medical management; acamprosate no effect; no additive benefit.
- Subtopic
- Alcohol
- Design
- 9-arm RCT, USA
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- NICE CG115 Alcohol
- Source
- Anton RF, et al. JAMA. 2006;295(17):2003-2017.doi 10.1001/jama.295.17.2003
Discussion & critique
Established a flexible pharma + behavioural toolkit; the long-debated acamprosate signal failed in this US sample.